3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Breast Neoplasms
24
Neoplasm Metastasis
11
Stomach Neoplasms
6
Pancreatic Neoplasms
4
Ovarian Neoplasms
4
Endometrial Neoplasms
4
Colorectal Neoplasms
4
Salivary Gland Neoplasms
3
Esophageal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Brain Neoplasms
3
Adenocarcinoma
3
Triple Negative Breast Neoplasms
2
Recurrence
2
Prostatic Neoplasms
2
Neoplasms
2
Adenocarcinoma Of Esophagus
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Unresectable Locally Recurrent Breast Cancer
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Osteosarcoma
1
Interventions
Paclitaxel
10
Carboplatin
6
Bevacizumab
5
liposomal doxorubicin
4
Topotecan
3
Cyclophosphamide
3
pembrolizumab
2
oregovomab
2
olaparib
2
niraparib
2
fludarabine
2
Nivolumab
2
Drug Therapy
2
trastuzumab deruxtecan
1
rucaparib
1
ribociclib
1
palbociclib
1
mirvetuximab soravtansine
1
isoquercitrin
1
irinotecan sucrosofate
1
fludarabine phosphate
1
denileukin diftitox
1
anlotinib
1
Tinzaparin
1
Saline Solution
1
Propranolol
1
Preoperative Exercise
1
Platinum
1
Palliative Care
1
Neoadjuvant Therapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Ovarian Epithelial
×
trastuzumab deruxtecan
×
90 days
×
Clear all
NCT06819007
2026-05-26
DO-01
Daiichi Sankyo
Phase 3
Recruiting
582 enrolled